Clearside Biomedical, Inc. (CLSD)

USD 0.77

(3.23%)

Market Cap (In USD)

59.76 Million

Revenue (In USD)

8.22 Million

Net Income (In USD)

-32.48 Million

Avg. Volume

206.05 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.92-2.12
PE
-1.65
EPS
-0.47
Beta Value
2.332
ISIN
US1850631045
CUSIP
185063104
CIK
1539029
Shares
75843500.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Employee Count
-
Website
https://www.clearsidebio.com
Ipo Date
2016-06-02
Details
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.